001462167 000__ 05111nam\a2200541\i\4500
001462167 001__ 1462167
001462167 003__ OCoLC
001462167 005__ 20230503003325.0
001462167 006__ m\\\\\o\\d\\\\\\\\
001462167 007__ cr\un\nnnunnun
001462167 008__ 230406s2023\\\\sz\a\\\\o\\\\\000\0\eng\d
001462167 020__ $$a9783031243554$$q(electronic bk.)
001462167 020__ $$a3031243552$$q(electronic bk.)
001462167 020__ $$z9783031243547
001462167 0247_ $$a10.1007/978-3-031-24355-4$$2doi
001462167 035__ $$aSP(OCoLC)1375086042
001462167 040__ $$aGW5XE$$beng$$erda$$epn$$cGW5XE
001462167 049__ $$aISEA
001462167 050_4 $$aRM281
001462167 08204 $$a615.3/72$$223/eng/20230406
001462167 24500 $$aVaccines for neglected pathogens :$$bstrategies, achievements and challenges : focus on leprosy, leishmaniasis, melioidosis and tuberculosis /$$cMyron Christodoulides, editor.
001462167 264_1 $$aCham :$$bSpringer,$$c2023.
001462167 300__ $$a1 online resource (vi, 344 pages) :$$billustrations (some color)
001462167 336__ $$atext$$btxt$$2rdacontent
001462167 337__ $$acomputer$$bc$$2rdamedia
001462167 338__ $$aonline resource$$bcr$$2rdacarrier
001462167 5050_ $$aPreface by Prof Myron Christodoulides, University of Southampton, UK.-1. Introduction chapter on the VALIDATE network -- (Prof Helen McShane, Director Oxford NIHR Biomedical Research Centre, University of Oxford, UK and Samantha Vermaak, The Jenner Institute Laboratories, Oxford, UK) -- Part I: Leprosy -- 2. Leprosy challenges to vaccine developers -- (Dr Hua Wang, University of Glasgow, UK) -- 3. Leprosy vaccine development -- (Dr Khushboo Borah, University of Surrey, UK) -- Part II: Tuberculosis -- 4. Biomarkers in tuberculosis vaccine development -- (Dr Kenneth Akwue, University of the Witwatersrand, Johannesburg, South Africa) -- 5. Tuberculosis correlates of protection (Dr Rachel Tanner, The Jenner Institute Laboratories, Oxford, UK), -- Animal models for tuberculosis (Dr. Hao Li, China Agricultural University, Beijing, China) -- 7. BCG vaccination -- (Dr Hazel Morrison, The Jenner Institute Laboratories, Oxford, UK) -- 8. Vaccination strategies for Buruli ulcer disease (Dr Rachel Simmonds, University of Surrey, UK) -- 9. Fermentation in vaccine development (BCG) (Dr. Joanna Bacon, Public Health England, UK Government, London, UK) -- Part III: Leishmaniasis: 10. Human leishmaniasis vaccination -- (Dr Ali Bordbar, Institute Pasteur of Iran, Tehran, Iran) -- 11. Aspects of human leishmaniasis vaccine use -- (Dr Olayinka Osuolale, Elizade University, Ilara-Mokin, Nigeria) -- 12. Human challenge model for developing leishmaniasis vaccines (Prof Paul Kaye, University of York, UK) -- 13. Canine leishmaniasis vaccines -- (Prof Eduardo Coelho, Federal University of Minas Gerais, Belo Horizonte, Brazil and Prof Myron Christodoulides, University of Southampton, UK) -- Part IV: Melioidosis -- 14. Vaccines for melioidosis (Prof Chiranjay Mukhopadhyay, Kasturba Medical College, Manipal, India) -- 15. West Africa burden of disease (Dr Tukur Ismail, Zamfara State Primary Healthcare Board, Gusau, Nigeria).
001462167 5060_ $$aOpen access.$$5GW5XE
001462167 520__ $$aThis book reviews successes and (remaining) challenges in vaccine development for the selected Neglected Tropical Diseases (NTD) of Leprosy, Leishmaniasis, Meliodoisis and Tuberculosis, which are a continuous burden for millions of people in affected areas worldwide. Written by frontline researchers, the volume deep-dives into different vaccine strategies, provides biotechnological background information and also tackles animal models in NTD therapeutics research. By bringing together state-of-the-art expert knowledge, the book contributes to the aim of ultimately ending the epidemics of neglected tropical diseases, complying with UN Sustainable Development Goal 3, Health and Well-Being.The volume highlights the activities of the research network VALIDATE (VAccine deveLopment for complex Intracellular neglecteD pAThogEns), funded by the Medical Research Council in the UK. The four NTDs discussed in the book were selected as these are in the focus of VALIDATE’s research. The book targets scientists and clinicians working on NTDs, as well as all readers with a background in biomedicine and interest in vaccine development. This is an open access book.
001462167 588__ $$aOnline resource; title from PDF title page (SpringerLink, viewed April 6, 2023).
001462167 650_0 $$aVaccines.
001462167 650_0 $$aDiseases.
001462167 655_0 $$aElectronic books.
001462167 7001_ $$aChristodoulides, Myron,$$eeditor.
001462167 852__ $$bebk
001462167 85640 $$3Springer Nature$$uhttps://link.springer.com/10.1007/978-3-031-24355-4$$zOnline Access$$91397441.2
001462167 909CO $$ooai:library.usi.edu:1462167$$pGLOBAL_SET
001462167 980__ $$aBIB
001462167 980__ $$aEBOOK
001462167 982__ $$aEbook
001462167 983__ $$aOnline
001462167 994__ $$a92$$bISE